First Bank & Trust’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $695K | Hold |
7,680
| – | – | 0.1% | 145 |
|
|
2026
Q1 | $615K | Buy |
7,680
+1,865
| +32% | +$154K | 0.1% | 136 |
|
|
2025
Q4 | $496K | Sell |
5,815
-280
| -5% | -$23K | 0.08% | 160 |
|
|
2025
Q3 | $474K | Sell |
6,095
-320
| -5% | -$25K | 0.08% | 154 |
|
|
2025
Q2 | $502K | Buy |
6,415
+82
| +1% | +$6.12K | 0.09% | 140 |
|
|
2025
Q1 | $459K | Buy |
6,333
+219
| +4% | +$15.7K | 0.09% | 143 |
|
|
2024
Q4 | $453K | Sell |
6,114
-5,977
| -49% | -$418K | 0.09% | 145 |
|
|
2024
Q3 | $798K | Sell |
12,091
-9,845
| -45% | -$715K | 0.15% | 100 |
|
|
2024
Q2 | $2.03M | Buy |
21,936
+956
| +5% | +$84.7K | 0.41% | 56 |
|
|
2024
Q1 | $2M | Buy |
20,980
+490
| +2% | +$41.2K | 0.41% | 57 |
|
|
2023
Q4 | $1.56M | Sell |
20,490
-3,108
| -13% | -$216K | 0.38% | 68 |
|
|
2023
Q3 | $1.63M | Sell |
23,598
-55
| -0.2% | -$4.42K | 0.43% | 58 |
|
|
2023
Q2 | $2.23M | Buy |
23,653
+1,288
| +6% | +$112K | 0.57% | 43 |
|
|
2023
Q1 | $1.85M | Buy |
22,365
+3,750
| +20% | +$295K | 0.49% | 45 |
|
|
2022
Q4 | $1.39M | Sell |
18,615
-3,481
| -16% | -$268K | 0.39% | 63 |
|
|
2022
Q3 | $1.83M | Buy |
22,096
+2,200
| +11% | +$212K | 0.67% | 37 |
|
|
2022
Q2 | $1.89M | Buy |
19,896
+3,711
| +23% | +$384K | 0.62% | 39 |
|
|
2022
Q1 | $1.91M | Buy |
16,185
+1,820
| +13% | +$204K | 0.59% | 40 |
|
|
2021
Q4 | $1.86M | Buy |
14,365
+280
| +2% | +$32.7K | 0.78% | 33 |
|
|
2021
Q3 | $1.59M | Buy |
14,085
+24
| +0.2% | +$2.74K | 0.73% | 37 |
|
|
2021
Q2 | $1.46M | Sell |
14,061
-259
| -2% | -$24.4K | 0.7% | 41 |
|
|
2021
Q1 | $1.2M | Buy |
14,320
+4,251
| +42% | +$359K | 0.6% | 47 |
|
|
2020
Q4 | $919K | Sell |
10,069
-5,205
| -34% | -$432K | 0.58% | 51 |
|
|
2020
Q3 | $1.22M | Sell |
15,274
-6,293
| -29% | -$491K | 0.81% | 39 |
|
|
2020
Q2 | $1.49M | Buy |
21,567
+8,133
| +61% | +$578K | 1.12% | 29 |
|
|
2020
Q1 | $845K | Buy |
13,434
+834
| +7% | +$60.1K | 0.76% | 39 |
|
|
2019
Q4 | $980K | Sell |
12,600
-1,200
| -9% | -$93.7K | 0.71% | 43 |
|
|
2019
Q3 | $1.01M | Buy |
13,800
+456
| +3% | +$32K | 0.76% | 41 |
|
|
2019
Q2 | $822K | Buy |
13,344
+204
| +2% | +$12.3K | 0.66% | 49 |
|
|
2019
Q1 | $838K | Sell |
13,140
-2,190
| -14% | -$125K | 0.65% | 54 |
|
|
2018
Q4 | $783K | Buy |
15,330
+474
| +3% | +$24K | 0.66% | 50 |
|
|
2018
Q3 | $714K | Hold |
14,856
| – | – | 0.54% | 66 |
|
|
2018
Q2 | $721K | Buy |
14,856
+1,659
| +13% | +$77.4K | 0.55% | 62 |
|
|
2018
Q1 | $614K | Sell |
13,197
-30
| -0.2% | -$1.3K | 0.49% | 64 |
|
|
2017
Q4 | $497K | Sell |
13,227
-231
| -2% | -$8.48K | 0.39% | 74 |
|
|
2017
Q3 | $490K | Buy |
13,458
+141
| +1% | +$5.38K | 0.4% | 71 |
|
|
2017
Q2 | $525K | Buy |
13,317
+228
| +2% | +$8.32K | 0.44% | 68 |
|
|
2017
Q1 | $410K | Buy |
13,089
+10,599
| +426% | +$332K | 0.35% | 76 |
|
|
2016
Q4 | $78K | Buy |
+2,490
| New | +$80.7K | 0.07% | 182 |
|
Other funds holding EW
WT
NONA
SIM
OIAM
FFM
NO
First Bank & Trust's EW Position: Q2 2026 in Review
First Bank & Trust held its Edwards Lifesciences (EW) position steady in Q2 2026 at 7,680 shares worth $695K. The position accounts for 0.1% of the portfolio, ranked #145.
First Bank & Trust first reported a position in EW in Q4 2016 and has held it in 39 quarters since. The position peaked at $2.23M in Q2 2023. 227 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- First Bank & Trust held 7,680 shares of Edwards Lifesciences worth $695K as of Q2 2026.
- First Bank & Trust left its Edwards Lifesciences share count unchanged in Q2 2026.
- Edwards Lifesciences made up 0.1% of First Bank & Trust's portfolio in Q2 2026, its #145 holding.
- First Bank & Trust first reported a position in Edwards Lifesciences in Q4 2016 and has held it in 39 quarters since.
- First Bank & Trust's Edwards Lifesciences position peaked at $2.23M in Q2 2023.
- 227 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on First Bank & Trust's 13F filing for Q2 2026, filed 9 Jul 2026.